Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00693654
Other study ID # IRB00000656
Secondary ID 31648
Status Completed
Phase Phase 4
First received
Last updated
Start date November 2006
Est. completion date October 2008

Study information

Verified date August 2018
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate the efficacy of SARNA Sensitive Lotion in the treatment of uremic pruritus in adult hemodialysis patients in a double-blind Controlled comparative trial.


Description:

This was a 4-week, randomized, double-blind, controlled study. Fourteen subjects received treatment lotion (1% pramoxine HCl) and the remaining 14 received a bland emollient (Cetaphil lotion). A target lesion limited to one anatomic site, excluding face and genitals, was selected at baseline. Each subject was instructed to apply lotion twice daily to all affected areas of pruritus for four weeks. The use of any other topical or systemic medication to treat uremic pruritus was not permitted while participating in the study. Subjects were clinically evaluated for erythema, xerosis, lichenification and overall severity at baseline, week 1, and week 4 (end of study)


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 2008
Est. primary completion date November 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Male or female patients 18 years of age to 70 years of age.

- A diagnosis of moderate to severe pruritus.

- At least 3 episodes of itch over a period of 2 weeks, each lasting for 2 minutes or more.

- Symptoms of itch in regular pattern over 6 months.

- Itch Visual analog scale (VAS) of 3cm or more out of 10 cm.

- All subjects will be end stage renal failure patients undergoing hemodialysis for at least 3 months, who have substantial pruritus for more than 6 months. Substantial pruritus is defined as persistent pruritus impairing sleep or daytime activity.

- Ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study

- The ability to understand and sign a written informed consent form, which must be obtained prior to treatment.

Exclusion Criteria:

- Presence of infection (as defined by the investigator) on the area to be treated.

- Subjects with history of pruritus predating renal failure and subjects with skin disease unrelated to uremia, such as atopic dermatitis, will be excluded.

- Use of systemic medications for treatment of pruritus including corticosteroids within the past 4 weeks and during the study.

- Use of topical medications for treatment of pruritus, including corticosteroids, within the past week.

- Pregnant women, women who are breast feeding, or women of child bearing potential who are not practicing an acceptable method of birth control (abstinence, birth control pill/patch, barrier with spermicidal jelly, IUD, etc.), as determined by the investigator. Acceptable contraception must be used during the entire study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sarna
Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
Cetaphil
Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid

Locations

Country Name City State
United States Wake Forest University Health Sciences Dermatology Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Stiefel, a GSK Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Investigator Global Assessment Investigator's Global Assessment Disease Severity is based on the following scale:
0 = completely clear: except for possible residual hyper pigmentation
= almost clear: very significant clearance (about 90%)
= Marked improvement: significant improvement (about 75%)
= Moderate improvement: intermediate between slight and marked; representing about 50% improvements
= Slight improvement: some improvement (about 25%); however, significant disease remaining
= No change (moderate to severe disease)
= Worse
Disease severity assessed at baseline and 4 weeks, week 4 reported
Secondary VAS of Pruritus Subject's self assessment of itching based on a 100 mm visual analog scale with 0 being no itching and 10 being most severe itching Assessed at baseline and 4 weeks, week 4 reported
See also
  Status Clinical Trial Phase
Completed NCT04518618 - Effect of Intrathecal Naloxone in the Incidence of Pruritis After C.S N/A
Completed NCT00323154 - Nalbuphine for the Treatment of Opioid Induced Pruritus in Children Phase 3
Completed NCT03816891 - Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis Phase 2
Recruiting NCT05936567 - Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Phase 2
Completed NCT01114672 - A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients Phase 4
Not yet recruiting NCT06226610 - Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic Phase 2
Withdrawn NCT02909569 - Relieving Chronic Itch: Oral Medication Phase 2